Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

CTI Biopharma stock

CTIC
US12648L6011
A2DJWX

Price

9.09
Today +/-
+0
Today %
+0 %

CTI Biopharma stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the CTI Biopharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CTI Biopharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CTI Biopharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CTI Biopharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CTI Biopharma Stock Price History

DateCTI Biopharma Price
6/23/20239.09 undefined
6/22/20239.09 undefined

CTI Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into CTI Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CTI Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CTI Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CTI Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CTI Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CTI Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CTI Biopharma’s growth potential.

CTI Biopharma Revenue, EBIT and net profit per share

DateCTI Biopharma RevenueCTI Biopharma EBITCTI Biopharma Net Income
2030e600.47 M undefined0 undefined0 undefined
2029e537.64 M undefined334.66 M undefined0 undefined
2028e469.3 M undefined276.01 M undefined0 undefined
2027e553.52 M undefined315.74 M undefined211.19 M undefined
2026e473.77 M undefined214.31 M undefined136.87 M undefined
2025e345.55 M undefined162.45 M undefined87.97 M undefined
2024e257.94 M undefined87.33 M undefined53.36 M undefined
2023e127.1 M undefined-23.11 M undefined-37.41 M undefined
202253.95 M undefined-79.8 M undefined-92.99 M undefined
20210 undefined-95.33 M undefined-97.91 M undefined
20200 undefined-43.57 M undefined-52.45 M undefined
20193.35 M undefined-39.92 M undefined-40.02 M undefined
201826.29 M undefined-32.24 M undefined-29.4 M undefined
201725.15 M undefined-39.52 M undefined-45.02 M undefined
201657.41 M undefined-49.16 M undefined-52.01 M undefined
201516.12 M undefined-116.67 M undefined-122.62 M undefined
201460.08 M undefined-86.23 M undefined-95.99 M undefined
201334.68 M undefined-41.37 M undefined-49.64 M undefined
20120 undefined-100.56 M undefined-115.28 M undefined
20110 undefined-73.19 M undefined-121.08 M undefined
2010320,000 undefined-78.25 M undefined-147.56 M undefined
200980,000 undefined-87.83 M undefined-116.76 M undefined
200811.43 M undefined-86.73 M undefined-202.91 M undefined
2007130,000 undefined-132.99 M undefined-148.31 M undefined
200680,000 undefined-98.01 M undefined-135.82 M undefined
200516.09 M undefined-116.16 M undefined-102.51 M undefined
200429.59 M undefined-240.83 M undefined-252.3 M undefined
200324.77 M undefined-122.59 M undefined-130.03 M undefined

CTI Biopharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e2029e2030e
000091113006162429160011000034601657252630053127257345473553469537600
-----22.2218.18---166.6750.0020.83-44.83--------76.47-73.33256.25-56.144.00-88.46---139.62102.3634.2437.1016.91-15.1914.5011.73
----555.56454.55100.00--83.33100.0095.8396.5593.75--72.73----100.0098.3387.5098.2596.0096.151,666.67--94.3439.3719.4614.4910.579.0410.669.318.33
000000130051623281500800003459145624250005000000000
-5-15-19-19-13-23-24-41-52-81-49-130-252-102-135-148-202-116-147-121-115-49-95-122-52-45-29-40-52-97-92-375387136211000
-200.0026.67--31.5876.924.3570.8326.8355.77-39.51165.3193.85-59.5232.359.6336.49-42.5726.72-17.69-4.96-57.3993.8828.42-57.38-13.46-35.5637.9330.0086.54-5.15-59.78-243.2464.1556.3255.15---
00000000000000.010.010.020.11.5368.463.435.8111.4214.8518.8427.9536.4556.0757.9771.1490.12114.6900000000
---------------------------------------
Details

Keystats

Revenue and Growth

The CTI Biopharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CTI Biopharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                       
21.93170.446.423.9154.9255.9140.391.6115.968.953.818.310.737.822.647.150.471.670.9128.24427.26733.752.565.4579.94
003.73.300.11.52.220.92.300.1100000.220.30.40000015.39
0000.60.41.53.41.94.70.10.20.607.500000007.81.300000
000000.210.910.9000.300001.65.14.22.81.50.600000.73
00.30.10.90.70.83.66.26.110.135.710.13.994.44.348.23.63.43.72.117.91.81.91.92.933.34
21.931.374.251.225157.5265.4151.5105.4127.9107.164.522.628.242.226.951.160.280.580.513555.84768.835.654.468.3899.4
5.75.15.96.854.38.411.711.322.412.37.964.33.43.43.66.85.54.63.732.41.84.62.93.292.08
00000000000005.800000000000000
0.20.20.100003.500000000000000000000
0000016.79.42.71.34.22.21.7160000000000000023.23
0000010.18.112.117.117.117.117.117.117.117.117.1000000000000
0.20.50.20.10.81.512.55.610.913.516.810.611.88.96.96.27.66.67.77.15.555.65.56.110.771.23
6.15.86.26.95.832.638.435.640.657.248.437.350.936.127.426.711.213.413.211.79.2887.310.73.94.0626.53
2837.180.458.130.8190.1303.8187.1146185.1155.5101.873.564.369.653.662.373.693.792.2144.263.85576.146.358.372.43125.93
                                                       
30.552.3006.21.500000026.28.4006.7000001.10.10.10.10.10.13
0.050.050.170.170.170.390.40.390.390.650.720.860.981.191.421.581.741.871.932.022.162.172.222.292.32.372.432.5
-60.1-74.1-97.1-122.1-158.4-210.3-290.6-340.5-470.5-722.8-825.3-961.1-1,109.4-1,312.3-1,429.1-1,576.6-1,714.8-1,830.1-1,879.7-1,975.7-2,098.3-2,150.3-2,195.3-2,224.7-2,263.6-2,328-2,425.92-2,518.91
00000100700-1,100-6,800-700-3,400-1,200-4,000-7,800-8,400-8,000-7,900-8,000-8,000-6,000-6,400-6,600-6,300-10,600-12,00000-35
0000000000000000-0.2-0.2-0.4-0.5-0.50000000
21.93071.847.120.9177.9109.543.4-82.5-70.7-107.2-101.6-107.9-123.6-18.6-4.728.634.645.241.752.113.421.858.823.740.13.77-17.58
1.10.70.21.11.21.11.22.447.33.40.66.69.37.365.812.15.16.410.67.22.64.501.63.892.01
1.43.14.74.84.98.411.515.8272517.628.62629.314.81111.110.29.519.722.124.813.912.913.69.413.8830.18
1.11.21.81.21.11.62.63.32.51.835.21.13.71.41.710.42.41.22.30.72.30.90.11.61.51
0000000000000000000000000000
00000000006.9019.8040.422.3003.2937.47.90.44.84.84.547.3847.94
3.656.77.17.211.115.321.533.534.130.934.453.542.363.94117.922.720.236.372.440.619.223.118.517.166.6581.13
2.6223.92.71.1176.5119.7193.8195.2231.2168.6127.5145.323.64.20010.28.419.111.313.69.34.50061.13
0000000000000000000000000000
0000002.42.11.326.40.60.50.40.30.913.516.418.120.79.15.34.164.65.41.22.021.23
2.6223.92.71.1178.9121.8195.1221.6231.8169.1127.9145.624.517.716.418.130.917.524.415.419.613.99.91.22.0262.37
6.278.7119.912.2194.2143.3228.6255.7262.7203.5181.4187.988.458.734.340.851.153.896.85638.83728.418.368.67143.5
28.13780.558.130.8190.1303.7186.7146.1185155.5101.973.564.369.85462.975.496.395.5148.969.460.695.852.158.472.43125.92
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of CTI Biopharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CTI Biopharma's financial health and stability.

Assets

CTI Biopharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CTI Biopharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CTI Biopharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CTI Biopharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-19-19-13-23-24-41-52-81-49-130-252-102-135-138-180-95-82-62-101-43-94-120-52-40-29-40-52-97-92
11111111119410964511221100000001
00000000000000000000000000000
100-2030-4211-2-1114478-6-5-32-397-8-6-137-27-7
010006512-50695-21-124193739841196431-2128916927
00000004108912341077123100124111016
00000000000000000000000000000
-16-16-11-23-21-29-36-61-88-107-148-125-116-103-80-88-63-60-62-35-39-95-76-39-39-27-42-84-81
-10-1-2-200-5-6-3-4-20-1-1-1-2-2-2-1000000000
3-8-11-381522-113-92802415460-1721421-2-2-20-10000-3028-912-73
5-8-10-351823-112-86862815962-172362300-1700000-3028-912-73
00000000000000000000000000000
0-1001-1-3168270-211280880-38-21014338-6-30-5-5-660
030226409171012660498551148910887443211404264066566
029216518167169-127288121028473944987875836152-73863-56197120
00000000-1602502400-16000000000004753
00000000000000-18-30000000000000
-124-13-411814-20-996-55-32-1-527-1524321057-840-6-5925-35
-18.14-17.18-12.39-26.23-24.51-30.51-36.95-67.83-95.19-110.48-152.78-127.25-117.14-105.37-82.12-89.67-65.14-63.16-65.72-37.49-39.88-95.28-76.82-39.35-39.85-27.82-42.23-84.89-81.19
00000000000000000000000000000

CTI Biopharma stock margins

The CTI Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CTI Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CTI Biopharma.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CTI Biopharma's sales revenue. A higher gross margin percentage indicates that the CTI Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CTI Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CTI Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CTI Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CTI Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CTI Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CTI Biopharma Margin History

CTI Biopharma Gross marginCTI Biopharma Profit marginCTI Biopharma EBIT marginCTI Biopharma Profit margin
2030e93.49 %0 %0 %
2029e93.49 %62.25 %0 %
2028e93.49 %58.81 %0 %
2027e93.49 %57.04 %38.15 %
2026e93.49 %45.24 %28.89 %
2025e93.49 %47.01 %25.46 %
2024e93.49 %33.86 %20.69 %
2023e93.49 %-18.18 %-29.43 %
202293.49 %-147.91 %-172.37 %
202193.49 %0 %0 %
202093.49 %0 %0 %
201993.49 %-1,191.64 %-1,194.63 %
201896.65 %-122.63 %-111.83 %
201798.53 %-157.14 %-179.01 %
201697.6 %-85.63 %-90.59 %
201587.97 %-723.76 %-760.67 %
201498.5 %-143.53 %-159.77 %
201399.6 %-119.29 %-143.14 %
201293.49 %0 %0 %
201193.49 %0 %0 %
201093.49 %-24,453.13 %-46,112.5 %
2009100 %-109,787.5 %-145,950 %
200871.65 %-758.79 %-1,775.24 %
200761.54 %-102,300.01 %-114,084.62 %
2006100 %-122,512.5 %-169,775.01 %
200596.77 %-721.94 %-637.1 %
200496.28 %-813.89 %-852.65 %
200396.61 %-494.91 %-524.95 %

CTI Biopharma Stock Sales Revenue, EBIT, Earnings per Share

The CTI Biopharma earnings per share therefore indicates how much revenue CTI Biopharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue CTI Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CTI Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CTI Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CTI Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CTI Biopharma Revenue, EBIT and net profit per share

DateCTI Biopharma Sales per ShareCTI Biopharma EBIT per shareCTI Biopharma Earnings per Share
2030e4.55 undefined0 undefined0 undefined
2029e4.08 undefined0 undefined0 undefined
2028e3.56 undefined0 undefined0 undefined
2027e4.2 undefined0 undefined1.6 undefined
2026e3.59 undefined0 undefined1.04 undefined
2025e2.62 undefined0 undefined0.67 undefined
2024e1.96 undefined0 undefined0.4 undefined
2023e0.96 undefined0 undefined-0.28 undefined
20220.47 undefined-0.7 undefined-0.81 undefined
20210 undefined-1.06 undefined-1.09 undefined
20200 undefined-0.61 undefined-0.74 undefined
20190.06 undefined-0.69 undefined-0.69 undefined
20180.47 undefined-0.57 undefined-0.52 undefined
20170.69 undefined-1.08 undefined-1.24 undefined
20162.05 undefined-1.76 undefined-1.86 undefined
20150.86 undefined-6.19 undefined-6.51 undefined
20144.05 undefined-5.81 undefined-6.46 undefined
20133.04 undefined-3.62 undefined-4.35 undefined
20120 undefined-17.31 undefined-19.84 undefined
20110 undefined-21.34 undefined-35.3 undefined
20100 undefined-1.14 undefined-2.16 undefined
20090.05 undefined-57.41 undefined-76.31 undefined
2008114.3 undefined-867.3 undefined-2,029.1 undefined
20076.5 undefined-6,649.5 undefined-7,415.5 undefined
20068 undefined-9,801 undefined-13,582 undefined
20051,609 undefined-11,616 undefined-10,251 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

CTI Biopharma business model

CTI Biopharma Corp is a biopharmaceutical company focused on the development of therapies for the treatment of cancer and other serious diseases. The company was founded in 1991 in Seattle, USA, and has been listed on the NASDAQ stock exchange since 1997. History: The history of CTI Biopharma Corp dates back to 1996 when the company launched its first product, a treatment for chronic myeloid leukemia. Since then, the company has continuously evolved and grown through the acquisition of other companies. In 2014, CTI Biopharma Corp merged with the French companies Cell Therapeutics, and in 2015, it acquired the Italian company Chroma Therapeutics. Business model: CTI Biopharma Corp's business model focuses on the development and commercialization of cancer therapies. The company utilizes its expertise in biology, chemistry, and medicine to develop innovative therapies that target specific molecular targets in tumors. The therapies are developed and produced by CTI Biopharma Corp itself before being distributed by doctors and healthcare facilities. Different divisions: The different divisions of CTI Biopharma Corp focus on various areas of cancer research. The "Hematology" division investigates the treatment of blood diseases such as leukemia and lymphomas. "Oncology," on the other hand, deals with the treatment of solid tumors such as breast cancer and lung cancer. Additionally, CTI Biopharma Corp also works in the field of "Toxicology" by studying the compatibility of medications and their effects on the immune system. Products: CTI Biopharma Corp offers a variety of products, but its flagship product Pixuvri is considered the most outstanding. Pixuvri is a chemotherapy drug used for the treatment of aggressive B-cell non-Hodgkin lymphomas (NHL). The drug is already approved in Europe, where it has been marketed since 2012. Pixuvri is currently under evaluation by the Food and Drug Administration (FDA) for potential introduction into the US market. Another product from CTI Biopharma Corp is Pacritinib, a tablet form used for the treatment of myelofibrosis. Conclusion: CTI Biopharma Corp has specialized in the development of drugs for the treatment of cancer and other diseases over the years. The company has focused on different divisions such as oncology and toxicology and offers a variety of products, including Pixuvri and Pacritinib. The acquisition of Chroma Therapeutics and Cell Therapeutics further highlights CTI Biopharma Corp's expansion strategy. CTI Biopharma is one of the most popular companies on Eulerpool.com.

CTI Biopharma SWOT Analysis

Strengths

CTI Biopharma Corp possesses several strengths that contribute to its competitiveness:

  • Strong Research and Development (R&D) capabilities, driving innovation and new drug development.
  • A diverse portfolio of promising drug candidates, offering potential for future growth.
  • Established partnerships with leading pharmaceutical companies, providing access to resources and expertise.
  • Rich intellectual property (IP) portfolio, protecting the company's innovative ideas and technologies.
  • Experienced management team with a proven track record in the biopharmaceutical industry.

Weaknesses

Despite its strengths, CTI Biopharma Corp faces certain weaknesses that may hinder its success:

  • Limited financial resources compared to larger competitors, potentially affecting the pace of R&D and commercialization efforts.
  • Reliance on a small number of drug candidates, increasing the risk associated with clinical trial outcomes and regulatory approvals.
  • Potential vulnerability to changes in healthcare regulations and policies that could impact pricing and reimbursement.

Opportunities

CTI Biopharma Corp can leverage the following opportunities to enhance its position in the market:

  • Increasing demand for innovative therapies in the biopharmaceutical industry, presenting a growing market for the company's products.
  • Expansion into emerging markets and partnerships with regional players, tapping into new customer bases and revenue streams.
  • Advancements in technology and scientific understanding, providing additional avenues for drug discovery and development.
  • Collaboration with research institutions or universities to further expand knowledge and access to potential breakthroughs.

Threats

CTI Biopharma Corp should remain vigilant about potential threats that could impact its operations:

  • Intense competition from established pharmaceutical companies and smaller biotech startups, challenging market share and pricing.
  • Uncertainties related to the clinical trial process and regulatory approvals, leading to potential delays or cancellations of key drug candidates.
  • Risk of patent expirations or challenges from generic manufacturers, posing a threat to revenue and market exclusivity.
  • Global economic factors, such as recession or currency fluctuations, which may impact the overall demand and pricing of pharmaceutical products.

CTI Biopharma Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

CTI Biopharma Revenue by Segment

Segmente2018
Products-
  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

CTI Biopharma Revenue by Segment

Segmente2018
License and contract revenue26.29 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CTI Biopharma Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CTI Biopharma historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CTI Biopharma shares outstanding

The number of shares was CTI Biopharma in 2024 — This indicates how many shares 114.694 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue CTI Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CTI Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CTI Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CTI Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CTI Biopharma stock splits

In CTI Biopharma's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for CTI Biopharma.

CTI Biopharma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2023-0.12 -0.1  (15.54 %)2023 Q1
12/31/2022-0.1 -0.14  (-41.99 %)2022 Q4
9/30/2022-0.16 -0.13  (18.65 %)2022 Q3
6/30/2022-0.21 -0.21  (-2.19 %)2022 Q2
3/31/2022-0.42 -0.37  (12.38 %)2022 Q1
12/31/2021-0.29 -0.38  (-32.27 %)2021 Q4
9/30/2021-0.25 -0.26  (-2.65 %)2021 Q3
6/30/2021-0.21 -0.21  (1.96 %)2021 Q2
3/31/2021-0.22 -0.23  (-3.65 %)2021 Q1
12/31/2020-0.16 -0.2  (-24.46 %)2020 Q4
1
2
3
4
5
...
10

CTI Biopharma shareholders

%
Name
Stocks
Change
Date
12.13451 % State Street Global Advisors (US)16,002,9892,260,43512/31/2022
6.68261 % BVF Partners L.P.8,813,021012/31/2022
4.87271 % BlackRock Institutional Trust Company, N.A.6,426,136405,15212/31/2022
4.20730 % The Vanguard Group, Inc.5,548,591762,56812/31/2022
3.74136 % Stonepine Capital Management, LLC4,934,100-735,28812/31/2022
3.61144 % Millennium Management LLC4,762,7698,64112/31/2022
3.49297 % Sofinnova Investments, Inc4,606,527994,15112/31/2022
2.95248 % Bleichroeder LP3,893,730-50,00012/31/2022
2.86420 % Bain Capital Life Sciences Investors, LLC3,777,3083,777,30812/31/2022
2.80759 % Lion Point Capital, L.P.3,702,651-686,89512/31/2022
1
2
3
4
5
...
10

CTI Biopharma Executives and Management Board

Dr. Adam Craig

(56)
CTI Biopharma President, Chief Executive Officer, Interim Chief Medical Officer, Director (since 2017)
Compensation 2.39 M

Mr. David Kirske

(67)
CTI Biopharma Chief Financial Officer, Executive Vice President, Secretary
Compensation 884,476

Ms. Diane Parks

(70)
CTI Biopharma Non-Executive Independent Director
Compensation 294,936

Dr. Laurent Fischer

(58)
CTI Biopharma Non-Executive Independent Chairman of the Board
Compensation 237,356

Mr. Michael Metzger

(51)
CTI Biopharma Non-Executive Independent Director
Compensation 215,856
1
2

CTI Biopharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer-0,080,710,08-0,66-0,59-0,16
1

Most common questions regarding CTI Biopharma

What values and corporate philosophy does CTI Biopharma represent?

CTI Biopharma Corp represents values of innovation, dedication, and commitment to improving patients' lives. With a focus on developing transformative therapies, CTI Biopharma Corp aims to address unmet medical needs and advance the field of oncology. The company embraces a patient-centric approach, driven by a strong corporate philosophy that places integrity, excellence, and collaboration at its core. CTI Biopharma Corp's ongoing research and development efforts aim to make significant advancements in the treatment of blood-related cancers. Through its innovative pipeline and strategic partnerships, the company is dedicated to making a positive impact on the healthcare industry and ultimately improving patient outcomes.

In which countries and regions is CTI Biopharma primarily present?

CTI Biopharma Corp is primarily present in the United States.

What significant milestones has the company CTI Biopharma achieved?

CTI Biopharma Corp has achieved several significant milestones. Firstly, the company successfully obtained FDA approval for its product Pixuvri®, a treatment for adult patients with a certain type of non-Hodgkin lymphoma. Additionally, CTI Biopharma Corp has received FDA Fast Track designation for pacritinib, an investigational treatment for patients with myelofibrosis. The company also entered into a licensing agreement with Baxter International Inc. for rights to commercialize Pixuvri® in certain territories. Furthermore, CTI Biopharma Corp has made progress in advancing its pipeline, with ongoing clinical trials focusing on the development of innovative treatments in various therapeutic areas. Overall, the company's achievements highlight its commitment to delivering novel therapies for the benefit of patients.

What is the history and background of the company CTI Biopharma?

CTI Biopharma Corp, a leading biopharmaceutical company, has a rich history and background. Established in 1991 and headquartered in Seattle, Washington, CTI focuses on developing novel therapies for blood-related cancers. The company initially operated under the name Cell Therapeutics, Inc., and rebranded as CTI Biopharma Corp in 2014. With a strong emphasis on research and innovation, CTI has made significant strides in cancer treatment, particularly in areas like stem cell transplant and small molecule drug development. Today, CTI Biopharma Corp continues to be a renowned player in the biopharmaceutical industry, committed to advancing cutting-edge therapies for patients around the world.

Who are the main competitors of CTI Biopharma in the market?

The main competitors of CTI Biopharma Corp in the market are Jazz Pharmaceuticals, Inc., Incyte Corporation, and Celgene Corporation.

In which industries is CTI Biopharma primarily active?

CTI Biopharma Corp is primarily active in the biopharmaceutical industry.

What is the business model of CTI Biopharma?

The business model of CTI Biopharma Corp focuses on developing and commercializing novel targeted therapies for blood-related cancers. They specialize in research, development, and marketing of treatments that aim to improve the lives of patients with hematologic malignancies. Through innovative drug discovery and clinical trials, CTI Biopharma Corp aims to address unmet medical needs in the oncology field. With a strong emphasis on scientific advancements, the company strives to bring new treatment options to patients worldwide.

What is the P/E ratio of CTI Biopharma 2025?

The CTI Biopharma P/E ratio is 11.85.

What is the P/S ratio of CTI Biopharma 2025?

The CTI Biopharma P/S ratio is 3.02.

What is the Quality Investing of CTI Biopharma?

The Quality Investing for CTI Biopharma is 5/10.

What is the revenue of CTI Biopharma 2025?

The expected CTI Biopharma revenue is 345.55 M USD.

How high is the profit of CTI Biopharma 2025?

The expected CTI Biopharma profit is 87.97 M USD.

What is the business model of CTI Biopharma

CTI Biopharma Corp is a global company in the biopharmaceutical industry that specializes in the research, development, production, and marketing of innovative cancer therapies. The company is headquartered in Seattle, USA, and has continuously grown since its founding in 1991. CTI Biopharma Corp's business model is based on the research and development of new cancer therapies that target signaling pathways in tumor cells. The company utilizes advanced technologies such as protein engineering and hemato-oncology technology to identify and optimize new compounds. One of CTI Biopharma Corp's developed substances is Pacritinib, an inhibitor of JAK2 and FLT3 for the treatment of blood cancer. The medication is considered a potential alternative for patients who do not respond sufficiently to other drugs. Other therapeutics in advanced stages of development include Pracinostat, an HDAC inhibitor therapy for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as Resminostat, another HDAC inhibitor for the treatment of gastrointestinal tumors. CTI Biopharma Corp has its own research department and collaborations with leading scientific institutions and research organizations worldwide. This enables the company to effectively and timely advance the research and development of new therapies. Another important aspect of CTI Biopharma Corp's business model is cooperation with other companies and organizations in the biopharmaceutical industry. This involves the marketing and distribution of products as well as the exploration of new therapy areas. Overall, CTI Biopharma Corp's business model is focused on the long-term development and marketing of innovative cancer therapies. The company relies on close collaboration with scientific institutions, effective research and development processes, targeted marketing, and partnerships with other companies in the industry. Through this strategy, CTI Biopharma Corp is able to achieve and maintain continuous growth and a strong position in the cancer therapy market in the long run.

What is the CTI Biopharma dividend?

CTI Biopharma pays a dividend of 0 USD distributed over payouts per year.

How often does CTI Biopharma pay dividends?

The dividend cannot currently be calculated for CTI Biopharma or the company does not pay out a dividend.

What is the CTI Biopharma ISIN?

The ISIN of CTI Biopharma is US12648L6011.

What is the CTI Biopharma WKN?

The WKN of CTI Biopharma is A2DJWX.

What is the CTI Biopharma ticker?

The ticker of CTI Biopharma is CTIC.

How much dividend does CTI Biopharma pay?

Over the past 12 months, CTI Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CTI Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of CTI Biopharma?

The current dividend yield of CTI Biopharma is .

When does CTI Biopharma pay dividends?

CTI Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CTI Biopharma?

CTI Biopharma paid dividends every year for the past 0 years.

What is the dividend of CTI Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CTI Biopharma located?

CTI Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von CTI Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CTI Biopharma from 1/23/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/23/2025.

When did CTI Biopharma pay the last dividend?

The last dividend was paid out on 1/23/2025.

What was the dividend of CTI Biopharma in the year 2024?

In the year 2024, CTI Biopharma distributed 0 USD as dividends.

In which currency does CTI Biopharma pay out the dividend?

The dividends of CTI Biopharma are distributed in USD.

All fundamentals about CTI Biopharma

Our stock analysis for CTI Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CTI Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.